Literature DB >> 8977961

Influence of the HLA-DRB1 locus on susceptibility and severity in rheumatoid arthritis.

F C Hall1, D E Weeks, J P Camilleri, L A Williams, N Amos, C Darke, K Gibson, K Pile, B P Wordsworth, J D Jessop.   

Abstract

We examined HLA-DR genotype risk in 288 patients with rheumatoid arthritis who were carefully categorized for disease severity. Five hundred ethnically-matched bone-marrow donors were controls. A hierarchy of positive allelic associations was noted with DRB1*0401 (p < 10(-38), *0404,8 (p < 10(-43), *0405 (p < 10(-8), *10 (p < 10(-3) and *0101,2 (p < 10(-2), while DRB1*0403 was negatively associated (p = 0.02). The DRB1 genotype relative risks (and 95% CIs) for RA were: *0404,5,8/*0404,5,8 = 36.2 (15-87), *0401/*0404,5,8 = 31.3 (18-55), *401/*0401 = 18.8 (11-35), *0101,2/*0404,5,8 = 6.0 (2-14), *0101,2/*0401 = 6.4 (3-12), *0101,2/*0101,2 = 1.3 (0.3-6), *10/*0404,5,8 = 27.8 (5-148), *10/*0401 = 20.8 (5-89), *10/*0101,2 = 22.3 (5-96), *0404,5,8/DRX = 5.0 (3-8), *0401/DRX = 4.7 (3-7), *0101,2/DRX = 2.3 (1.4-4), *10/DRX = 3.4 (0.8-14). No significant correlation of DRB1 genotypes was found with severity of RA as judged by nodules or articular erosions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977961     DOI: 10.1093/qjmed/89.11.821

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  17 in total

1.  The relationship between the sibling recurrence-risk ratio and genotype relative risk.

Authors:  B A Rybicki; R C Elston
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

2.  HLA-DR-DQ haplotypes and genotypes in Finnish patients with rheumatoid arthritis.

Authors:  S Laivoranta-Nyman; T Möttönen; R Hermann; J Tuokko; R Luukkainen; M Hakala; P Hannonen; M Korpela; U Yli-Kerttula; A Toivanen; J Ilonen
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

3.  Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.

Authors:  Lindsey A Criswell; Kirsten A Pfeiffer; Raymond F Lum; Bonnie Gonzales; Jill Novitzke; Marlena Kern; Kathy L Moser; Ann B Begovich; Victoria E H Carlton; Wentian Li; Annette T Lee; Ward Ortmann; Timothy W Behrens; Peter K Gregersen
Journal:  Am J Hum Genet       Date:  2005-02-17       Impact factor: 11.025

Review 4.  Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis.

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Atsushi Hashimoto; Shigeto Tohma
Journal:  J Hum Genet       Date:  2015-04-23       Impact factor: 3.172

Review 5.  Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis.

Authors:  R M Nakamura
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

6.  HLA-DRB1-associated rheumatoid arthritis risk at multiple levels in African Americans: hierarchical classification systems, amino acid positions, and residues.

Authors:  Richard J Reynolds; Altan F Ahmed; Maria I Danila; Laura B Hughes; Peter K Gregersen; Soumya Raychaudhuri; Robert M Plenge; S Louis Bridges
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

Review 7.  Rheumatoid arthritis: a view of the current genetic landscape.

Authors:  M J H Coenen; P K Gregersen
Journal:  Genes Immun       Date:  2008-11-06       Impact factor: 2.676

8.  The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.

Authors:  Ct Chou; Ht Liao; Ch Chen; Ws Chen; Hp Wang; Ky Su
Journal:  Biomark Insights       Date:  2007-05-03

Review 9.  Current concepts in the pathogenesis of early rheumatoid arthritis.

Authors:  Arthur G Pratt; John D Isaacs; Derek L Mattey
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-02       Impact factor: 4.098

10.  A search for non-chromosome 6 susceptibility loci contributing to rheumatoid arthritis.

Authors:  Robert Culverhouse; Carol H Jin; Anthony L Hinrichs; Brian K Suarez
Journal:  BMC Proc       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.